Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310262 | 0.95 | PDE4B (0.68) | PDE4BADRB2CSF1RPDE4APDE4C | |
| SCHEMBL1312346 | 0.95 | PDE4B (0.76) | PDE4BADRB2PDE4APDE4CPDE4D | |
| SCHEMBL1311077 | 0.91 | PDE4B (0.72) | PDE4BADRB2CSF1RPDE4APDE4C | |
| SCHEMBL1312430 | 0.91 | PDE4B (0.76) | PDE4BADRB2CSF1RPDE4APDE4C | |
| SCHEMBL1309658 | 0.90 | PDE4B (0.73) | PDE4BADRB2PDE4APDE4CPDE4D | |
| SCHEMBL1310884 | 0.90 | PDE4B (0.70) | PDE4BADRB2CSF1RPDE4APDE4C | |
| SCHEMBL1309893 | 0.89 | PDE4B (0.76) | PDE4BADRB2CSF1RPDE4APDE4C | |
| SCHEMBL1310385 | 0.89 | PDE4B (0.62) | PDE4BADRB2PDE4APDE4CPDE4D | |
| SCHEMBL1310375 | 0.88 | PDE4B (0.63) | PDE4BADRB2PDE4APDE4CPDE4D | |
| SCHEMBL12116109 | 0.86 | PDE4B (0.54) | PDE4BCSF1RPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011143105-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | PDE4B 434/4885ADRB2 16/4885CSF1R 378/4885 |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | PDE4B 480/4885ADRB2 13/4885CSF1R 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.